TEST BANK
LILLEY'S PHARMACOLOGY FOR CANADIAN HEALTH CARE PRACTICE
KARA SEALOCK
4th Edition
TEST BANK
, lOMoAR cPSD| 3013804
lOMoAR cPSD| 3013804
Chapter 01: Nursing Practice in Canada and Drug Therapy
Sealock: Lilley’s Pharmacology for Canadian Health Care Practice, 4th Edition
MULTIPLE CHOICE
1. Which is a judgement about a particular patient’s potential need or problem?
a. A goal
b. An assessment
c. Subjective data
d. A nursing diagnosis
ANS: D
Nursing diagnosis is the phase of the nursing process during which a clinical judgement is made about
heath conditions and life processes or vulnerability for that response.
DIF: Cognitive Level: Knowledge
2. The patient is to receive oral furosemide (Lasix) every day; however, because the patient is unable to s
medication orally, as ordered. The nurse needs to contact the physician. What type of problem is this?
a. A “right time” problem
b. A “right dose” problem
c. A “right route” problem
d. A “right medication” problem
ANS: C
This is a “right route” problem: the nurse cannot assume the route and must clarify the route with the p
time” problem because the ordered frequency has not changed. This is not a “right dose” problem beca
an inability to swallow. This is not a “right medication” problem because the medication ordered will n
DIF: Cognitive Level: Application
3. The nurse has been monitoring the patient’s progress on his new drug regimen since the first dose and h
of possible adverse effects. What nursing process phase is the nurse practising?
a. Planning
b. Evaluation
c. Implementation
d. Nursing diagnosis
ANS: B
Monitoring the patient’s progress is part of the evaluation phase. Planning, implementation, and nursin
illustrated by this example.
DIF: Cognitive Level: Application
4. The nurse is caring for a patient who has been newly diagnosed with type 1 diabetes mellitus. Which st
outcome criterion for this patient?
a. The patient will follow instructions.
b. The patient will not experience complications.
c. The patient adheres to the new insulin treatment regimen.
d. The patient demonstrates safe insulin self-administration technique.
ANS: D
Having the patient demonstrate safe insulin self-administration technique is a specific and measurable o
instructions and avoiding complications are not specific criteria. Adherence to the new insulin treatmen
and would be difficult to measure.
DIF: Cognitive Level: Application
, lOMoAR cPSD| 3013804
6. The nurse is working during a very busy night shift, and the health care provider has just given the nurs
the telephone, but the nurse does not recall the route. What is the best way for the nurse to avoid medic
a. Recopy the order neatly on the order sheet, with the most common route indicated
b. Consult with the pharmacist for clarification about the most common route
c. Call the health care provider to clarify the route of administration
d. Withhold the drug until the health care provider visits the patient
ANS: C
If a medication order does not include the route, the nurse must ask the health care provider to clarify i
administration.
DIF: Cognitive Level: Application | Cognitive Level: Analysis
7. Which constitutes the traditional Five Rights of medication administration?
a. Right drug, right route, right dose, right time, and right patient
b. Right drug, the right effect, the right route, the right time, and the right patient
c. Right patient, right strength, right diagnosis, right drug, and right route
d. Right patient, right diagnosis, right drug, right route, and right time
ANS: A
The traditional Five Rights of medication administration were considered to be Right drug, Right route
Right patient. Right effect, right strength, and right diagnosis are not part of the traditional Five Rights
DIF: Cognitive Level: Comprehension
8. What correctly describes the nursing process?
a. Diagnosing, planning, assessing, implementing, and finally evaluating
b. Assessing, then diagnosing, implementing, and ending with evaluating
c. A linear direction that begins with assessing and continues through diagnosing,
planning, and finally implementing
d. An ongoing process that begins with assessing and continues with diagnosing,
planning, implementing, and evaluating
ANS: D
The nursing process is an ongoing, flexible, adaptable, and adjustable five-step process that begins with
through diagnosing, planning, implementing, and finally evaluating, which may then lead back to any o
DIF: Cognitive Level: Application
9. When the nurse is considering the timing of a drug dose, which is most important to assess?
a. The patient’s identification
b. The patient’s weight
c. The patient’s last meal
d. Any drug or food allergies
ANS: C
The pharmacokinetic and pharmacodynamic properties of the drug need to be assessed with regard to a
compatibility issues. The patient’s identification, weight, and drug or food allergies are not affected by
DIF: Cognitive Level: Application
10. The nurse is writing nursing diagnoses for a plan of care. Which reflects the correct format for her nurs
a. Anxiety
b. Anxiety related to new drug therapy
c. Anxiety related to anxious feelings about drug therapy, as evidenced by
statements such as “I’m upset about having to give myself shots”
d. Anxiety related to new drug therapy, as evidenced by statements such as “I’m
upset about having to give myself shots”
ANS: D
Formulation of nursing diagnoses is usually a three-step process. The only complete answer is “Anxiet
, lOMoAR cPSD| 3013804
Chapter 02: Pharmacological Principles
Sealock: Lilley’s Pharmacology for Canadian Health Care Practice, 4th Edition
MULTIPLE CHOICE
1. A npatient nis nreceiving ntwo ndifferent ndrugs, nwhich, nat ntheir ncurrent ndose nforms nand ndosages, nare
ncirculation ninnidentical namounts. nWhich nterm nbest ndenotes nthat nthe ndrugs nhave nthe nsame nabsorp
a. Equivalent
b. Synergistic
c. Compatible
d. Bioequivalent
ANS: n D
Two ndrugs nabsorbed ninto nthe ncirculation nat nthe nsame namount n(in nspecific ndosage nforms) nhave nth
nthus, nthey narenbioequivalent. n“Equivalent” nis nincorrect nbecause nthe nterm n“bioavailability” nis nused
ndrug nabsorption. n“Synergistic” nis nincorrect nbecause nthis nterm nrefers nto ntwo ndrugs ngiven ntogethe
ngreater nthan nthe nsum nof nthe neffects nof neach ndrug ngiven nalone. n“Compatible” nis nincorrect nbecau
nterm nused nto nindicate nthat ntwo nsubstances ndo nnot nhave na nchemical nreaction nwhen nmixed n(or ngi
ndrugs) ntogether.
DIF: Cognitive nLevel: nComprehension
2. A npatient nis nreceiving nmedication nvia nintravenous ninjection. nWhich ninformation nshould nthe nnurse
n education?
a. The nmedication nwill ncause nfewer nadverse neffects nwhen ngiven nintravenously.
b. The nmedication nwill nbe nabsorbed nslowly ninto nthe ntissues nover ntime.
c. The nmedication’s naction nwill nbegin nfaster nwhen ngiven nintravenously.
d. Most nof nthe ndrug nis ninactivated nby nthe nliver nbefore nit nreaches nthe ntarget narea.
ANS: n C
Intravenous ninjections nare nthe nfastest nroute nof nabsorption. nThe nintravenous nroute ndoes nnot naffect
neffects, nthenintravenous nroute nis nnot na nslow nroute nof nabsorption, nand nthe nintravenous nroute ndoes
nof nthe ndrug nby nthe nliver nbefore nit nreaches nthe ntarget narea.
DIF: Cognitive nLevel: nComprehension
3. Which nis ntrue nregarding nparenteral ndrugs?
a. They nbypass nthe nfirst-pass neffect.
b. They ndecrease nblood nflow nto nthe nstomach.
c. They nare naltered nby nthe npresence nof nfood nin nthe nstomach.
d. They nexert ntheir neffects nwhile ncirculating nin nthe nbloodstream.
ANS: n A
Drugs ngiven nby nthe nparenteral nroute nbypass nthe nfirst-pass neffect, nbut nthey nstill nmust nbe nabsorbed
nbefore nthey ncannexert ntheir neffects. nEnteral ndrugs n(drugs ntaken norally), nnot nparenteral ndrugs, ndec
nstomach nand nare n altered nby nthe npresence nof nfood nin nthe nstomach. nParenteral ndrugs nmust nbe nab
ntissues nfrom nthe ncirculation nbefore nthey ncan nexert ntheir neffects; nthey ndo nnot nexert ntheir neffects
nbloodstream.
DIF: Cognitive nLevel: nAnalysis
4. A ndrug’s nhalf-life nis nbest ndefined nas
a. The ntime nit ntakes nfor nthe ndrug nto nelicit nhalf nits ntherapeutic nresponse.
b. The ntime nit ntakes none-half nof nthe noriginal namount nof na ndrug nto nreach
nthe ntargetncells.
c. The ntime nit ntakes none-half nof nthe noriginal namount nof na ndrug nto nbe nremoved
nfrom nthenbody.
d. The ntime nit ntakes none-half nof nthe noriginal namount nof na ndrug nto nbe
nabsorbed ninto nthencirculation.
